A detailed history of Black Rock Inc. transactions in Kempharm, Inc stock. As of the latest transaction made, Black Rock Inc. holds 2,697,052 shares of KMPH stock, worth $13.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,697,052
Previous 2,397,847 12.48%
Holding current value
$13.3 Million
Previous $11.8 Million 12.48%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
N/A
299,205 Added 12.48%
2,697,052 $13.3 Million
Q1 2024

May 10, 2024

SELL
N/A
-12,442 Reduced 0.52%
2,397,847 $11.8 Million
Q4 2023

Feb 13, 2024

BUY
N/A
259,839 Added 12.08%
2,410,289 $11.9 Million
Q3 2023

Nov 13, 2023

SELL
N/A
-52,627 Reduced 2.39%
2,150,450 $10.6 Million
Q2 2023

Aug 11, 2023

BUY
$4.94 - $6.29 $7.9 Million - $10.1 Million
1,599,899 Added 265.24%
2,203,077 $10.9 Million
Q1 2023

May 12, 2023

BUY
$4.13 - $6.27 $2,011 - $3,053
487 Added 0.08%
603,178 $3.32 Million
Q4 2022

Feb 13, 2023

SELL
$4.12 - $5.62 $1.01 Million - $1.38 Million
-244,920 Reduced 28.9%
602,691 $2.77 Million
Q3 2022

Nov 14, 2022

SELL
$4.5 - $6.85 $23,571 - $35,880
-5,238 Reduced 0.61%
847,611 $5.29 Million
Q2 2022

Aug 12, 2022

SELL
$4.02 - $5.21 $5.63 Million - $7.3 Million
-1,400,485 Reduced 62.15%
852,849 $3.8 Million
Q1 2022

May 12, 2022

BUY
$5.0 - $9.26 $88,960 - $164,753
17,792 Added 0.8%
2,253,334 $11.3 Million
Q4 2021

Feb 10, 2022

BUY
$7.6 - $10.26 $2.1 Million - $2.83 Million
276,104 Added 14.09%
2,235,542 $19.5 Million
Q3 2021

Nov 09, 2021

SELL
$8.72 - $13.31 $77,956 - $118,991
-8,940 Reduced 0.45%
1,959,438 $18.3 Million
Q2 2021

Aug 11, 2021

BUY
$8.52 - $15.47 $16.8 Million - $30.5 Million
1,968,378 New
1,968,378 $25.2 Million

Others Institutions Holding KMPH

About KEMPHARM, INC


  • Ticker KMPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,493,600
  • Market Cap $170M
  • Description
  • KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds t...
More about KMPH
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.